What You Should Know:
– As part of a collaboration agreement, Sentara also becomes the first of several U.S. health systems that will partner with Sensyne to implement new clinical algorithms to support patients with CKD and CHF. The agreement will enable the ethical application of clinical AI research by Sensyne through analyzing Sentara’s patient dataset to improve patient care and accelerate medical research.
– Sentara will join 11 UK NHS Trusts and U.S. Health Systems who are partners and shareholders in Sensyne Health. The new agreement is Sensyne’s third U.S. partnership since launching in the U.S. in December 2020. The addition of Sentara’s 3.6 million patients brings Sensyne’s combined total of de-identified patient data for medical research to 21.7 million patients.